Press coverage about Innocoll (NASDAQ:INNL) has trended somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Innocoll earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned news stories about the specialty pharmaceutical company an impact score of 45.2634723900683 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Innocoll (INNL) remained flat at $$2.35 during mid-day trading on Friday. Innocoll has a 52-week low of $0.53 and a 52-week high of $6.51. The company has a debt-to-equity ratio of -2.26, a quick ratio of 0.86 and a current ratio of 1.01. The firm has a market cap of $70.73 and a PE ratio of -1.42.
TRADEMARK VIOLATION WARNING: This piece was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/13/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-innocoll-innl-stock-price.html.
Innocoll Holdings Public Limited Company is a commercial-stage specialty pharmaceutical and medical device company with late-stage development programs. The Company operates through the segment of manufacture and sale of collagen-based pharmaceutical products. It utilizes collagen-based technology platform to develop its biodegradable and bioresorbable products and product candidates, which can be broken down by the body without the need for surgical removal or applied topically.
Receive News & Ratings for Innocoll Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innocoll and related companies with MarketBeat.com's FREE daily email newsletter.